Scott supervises all operations of Biovest’s Contract Manufacturing Division and mAbVault. He also oversees upstream production at Biovest’s Biologics Manufacturing Division, which supports the manufacturing of Dasiprotimut-T, an autologous adaptive immunotherapy vaccine targeting Indolent Follicular non-Hodgkins Lymphoma. Scott holds a B.S. in Medical Technology (ASCP) from the University of Wisconsin and has been with Biovest since 1989.